Search - tctmd.com

Displaying 1 - 20 of 36

Sort: Relevancy | Date

News Daily News

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Michael O'Riordan

September 18, 2025

News Daily News

Half of Patients Stop Semaglutide for Weight Loss by 1 Year

Todd Neale

September 18, 2025

News Daily News

Amylin Analogue Boosts Weight Loss When Added to GLP-1

L.A. McKeown

June 24, 2025

Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5

Michael O'Riordan

May 12, 2025

News Daily News

Newer Weight-Loss Drugs Not Cost-effective at Current Prices

Michael O'Riordan

March 18, 2025

News Daily News

CVD Hospitalization in Older Adults Higher in US Than in Denmark

Michael O'Riordan

February 07, 2025

News Daily News

European Medicines Agency Investigating GLP-1 Drugs and Eye Disease

L.A. McKeown

January 21, 2025

News Features

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Michael O'Riordan

January 17, 2025

News Daily News

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

Michael O'Riordan

December 04, 2024

News Opinion Editor's Corner

Olympic Hearts: Screening for CVD Among Team USA’s Athletes

Michael O'Riordan

July 31, 2024

News Conference News SCCT 2024

Coronary Calcium Scoring May Help Get Semaglutide to Highest-Risk Patients

Todd Neale

July 22, 2024

News Daily News

BP Reductions Last 5 Years After Bariatric Surgery: GATEWAY

Michael O'Riordan

February 07, 2024

News Daily News

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

Todd Neale

December 12, 2023

News Daily News

To Improve CV Care in US South Asians, Understand Unique ASCVD Risks: ACC

Yael L. Maxwell

April 12, 2023

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Daily News

Longer-Term ASCVD Risk Assessment Best for Younger Patients

Michael O'Riordan

February 16, 2023

News Daily News

Autism and Cardiometabolic Disease Often Go Hand in Hand

Caitlin E. Cox

February 06, 2023

News Daily News

Cardiorespiratory Fitness Is Key to Longevity, Regardless of Age, Sex, and Race

Yael L. Maxwell

August 09, 2022

News Daily News

CV Risk Factors, Disease Projected to Explode in Coming Decades

L.A. McKeown

August 01, 2022

News Daily News

‘Code Blue’ for the Dire CVD Health Status of Most US Adults

Michael O'Riordan

July 05, 2022

Advertisement

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Half of Patients Stop Semaglutide for Weight Loss by 1 Year

Amylin Analogue Boosts Weight Loss When Added to GLP-1

Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5

Newer Weight-Loss Drugs Not Cost-effective at Current Prices

CVD Hospitalization in Older Adults Higher in US Than in Denmark

European Medicines Agency Investigating GLP-1 Drugs and Eye Disease

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

Olympic Hearts: Screening for CVD Among Team USA’s Athletes

Coronary Calcium Scoring May Help Get Semaglutide to Highest-Risk Patients

BP Reductions Last 5 Years After Bariatric Surgery: GATEWAY

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

To Improve CV Care in US South Asians, Understand Unique ASCVD Risks: ACC

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Longer-Term ASCVD Risk Assessment Best for Younger Patients

Autism and Cardiometabolic Disease Often Go Hand in Hand

Cardiorespiratory Fitness Is Key to Longevity, Regardless of Age, Sex, and Race

CV Risk Factors, Disease Projected to Explode in Coming Decades

‘Code Blue’ for the Dire CVD Health Status of Most US Adults

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content